• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Adma Biologics (NQ: ADMA )

    19.39 -0.05 (-0.28%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,820,841
    Open 19.50
    Bid (Size) 19.21 (4)
    Ask (Size) 19.74 (4)
    Prev. Close 19.44
    Today's Range 19.18 - 19.60
    52wk Range 3.060 - 20.16
    Shares Outstanding 196,357,149
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Looking for growth without the hefty price tag? Consider NASDAQ:ADMA.
    Looking for growth without the hefty price tag? Consider NASDAQ:ADMA. 
    Via Chartmill
    In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics
    Via Benzinga

    Performance

    YTD
    +326.04%
    +326.04%
    1 Month
    +11.73%
    +11.73%
    3 Month
    +77.03%
    +77.03%
    6 Month
    +193.71%
    +193.71%
    1 Year
    +439.97%
    +439.97%

    More News

    Read More
    ADMA Biologics Set to Join S&P SmallCap 600 Index
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    Assessing ADMA Biologics: Insights From 4 Financial Analysts
    Via Benzinga
    What's Going On With ADMA Biologics Stock Monday?
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
    Via Investor's Business Daily
    'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
    Via Benzinga
    Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
    Via Investor's Business Daily
    Biohaven Stock Earns Relative Strength Rating Upgrade
    Via Investor's Business Daily
    SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
    Via Investor's Business Daily
    Immunome Stock Sees RS Rating Jump To 91
    Via Investor's Business Daily
    PTC Therapeutics Stock Earns RS Rating Upgrade To 83
    Via Investor's Business Daily
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
    Via Benzinga
    Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
    Via Investor's Business Daily
    ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
    Via Investor's Business Daily
    Beam Therapeutics Stock Earns RS Rating Jump To 85
    Via Investor's Business Daily
    Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist'
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.